Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company

MARSEILLE, France--(BUSINESS WIRE)--Apr 23, 2025-

The pharmaceutical laboratory could invest up to EUR 15 million in biotech through an increase in capital.

Innate Pharma regains its rights on CD123 targeting ANKET® and announces Sanofi’s intention to make a strategic investment in the Company

Innate Pharma regains its rights on CD123 targeting ANKET® and announces Sanofi’s intention to make a strategic investment in the Company Wed, 04/23/2025 - 07:00 Press Release in English 170.1 KB Communiqué de presse en français 162.43 KB mathilde Tue, 04/22/2025